• About the Company
  • Corporate Culture
  • Development History
  • Executives
  • Executives Video
  • About the Company


    Qingdao Primedicine Pharmaceutical Technology Co., Ltd. is a high-tech enterprise emphasizing on the research and development of first-in-class new drugs, and the development and commercialization of innovative drugs related to the central nervous system in the treatment of drug addiction, Alzheimer's disease, cerebral stroke, depression, schizophrenia, myocardial infarction, etc.

    Primedicine Pharmaceutical was established in September 2016 and is situated in the beautiful coastal city of Qingdao. It is the first full-time overseas academician team in Qingdao International Academician Park. Wang Yutian, Fellow of The Royal Society of Canada is the Chairman and the Chief Scientist of the company. The majority of the company’s team members have overseas educational background and work experience. The core members have world-class scientific research ability and extensive experience in clinical medical treatment and pharmaceutical management.

    The company’s current research product pipeline includes PMS-001 (AMPA receptor modulator), PMS-002 (NMDA receptor subtype allosteric modulator), PMS-003 (SREBP-1 inhibitor), PMS-004 (JNK kinase inhibitor), etc. Most of the compounds are a result of independent research and innovation by the company’s determined scientific and technological teams, and are protected under global patents.


    Copyright © 2020 Qingdao Primedicine Pharmaceutical Technology Co., Ltd. All right reserved

    龙8-long8(中国)唯一官方网站_产品2559 龙8-long8(中国)唯一官方网站_公司8220
    友情链接:尊龙凯时-人生就是博中国官方网站  凯发·k8国际(中国)首页登录  k8凯发(china)天生赢家·一触即发  凯发·k8(国际)-官方网站  九游会J9·(china)官方网站-真人游戏第一品牌  k8凯发(中国)天生赢家·一触即发  凯发·(中国)k8国际首页登录  尊龙凯时(中国区)人生就是搏  k8·凯发(国际)-官方网站